Meeting records about the paediatric oncology funding exception rule (8.1b) (part 2)

Further to my letter of 1 December 2022 please find a final response to your request, dated 2 November 2022, under the Official Information Act 1982 (OIA) for information relating to the Pharmaceutical Schedule funding exception rule (8.1b) for paediatric oncology. You asked:

…whether the topic of funding of paediatric cancer medicines (rule 8.1b) consulted on today has been discussed as an agenda item or matters arising at PTAC, CAC or Cancer Treatments Advisory Committee (previously CaTSoP). If so, can you please provide the record of that/those discussions/advice.

I am pleased to provide you with a copy of the record of the Cancer Treatments Advisory Committee (CTAC) (formerly CaTSoP) meeting of 26 May 2021, and the record of the Consumer Advisory Committee (CAC) meeting of 12 August 2022, attached with this response. Although you did not specifically request it, we have also included a copy of the memorandum to the CAC for its meeting of 12 August 2022 as this provides context for the record of the meeting.

Please note, we have withheld a small amount of information from the document provided where it is not related to the review of Schedule rule (8.1b) for paediatric oncology, i.e. where the information is out of scope of your request.

You have the right to make a complaint to the Ombudsman about our response to your OIA, under section 28(3) of the OIA. Details of how to make a complaint(external link) are on the Ombudsman’s website.

We are making our information more freely available, so we now publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.